Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | American Journal of Cardiology |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract |
| Doi | http://dx.doi.org/10.1016/j.amjcard.2015.05.022 |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | Hypertrophic cardiomyopathy; male sexual dysfunction; phosphodiesterase type 5; sildenafil |
| Description | The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy. |